Sean P. David, M.D., D.Phil.
Academic Appointments
- Clinical Associate Professor, Medicine - General Medical Disciplines
Key Documents
Contact Information
-
Clinical Offices
Stanford Family Medicine 211 Quarry Rd., Suite 405 MC: 5985 Palo Alto, CA 94304 Tel Work (650) 723-6963 Fax (650) 498-7750Practices at Stanford Hospital and Clinics and Lucile Packard Children's Hospital
- Academic Offices
Personal Information EmailAlternate Contact Randy Fauver Research Assistant EmailNot for medical emergencies or patient use
Professional Overview
Clinical Focus
- Family Medicine
- Pharmacogenomics
Administrative Appointments
- Clinical Associate Professor of Family & Community Medicine, Stanford University School of Medicine (2009 - present)
- Physician curator, PharmGKB (2010 - present)
- Clinical Associate Professor (secondary appointment), Stanford Prevention Research Center (2011 - present)
- Adjunct Associate Professor of Family Medicine, Brown Alpert Medical School (2009 - present)
- Director of Primary Care Genetics Laboratory & Translational Research Center, Memorial Hospital of Rhode Island/Brown Alpert Medical School (2002 - 2009)
- Director of C. Everett Koop Health Policy Fellowship, Brown Alpert Medical School (2003 - 2009)
Honors and Awards
- James C. Puffer, M.D./American Board of Family Medicine/Insitute of Medicine Anniversary Fellow, Institute of Medicine (2011 - 2013)
- Benjamin Meaker Visiting Professorship, University of Bristol (2010)
- Family Practice Scholar Award, Glaxo-Wellcome (1997)
- Deans Teaching Excellence Award, Brown Alpert Medical School (2001)
- Profiles in Competence Teaching Award, Brown Alpert Medical School (2002)
- Advanced Research Training Award, American Academy of Family Physicians (2001 2003)
Professional Education
| Residency: | NH Dartmouth Family Practice Residency NH (1998) |
| Medical Education: | University of Washington School of Medicine WA (1995) |
| BS: | University of Washington, Zoology (1990) |
| SM: | Harvard School of Public Health, Health & Social Behavior (1999) |
| PhD Training: | University of Oxford, UK (2006) |
| Internship: | NH Dartmouth Family Practice Residency NH (1996) |
Community and International Work
- Study of Tobacco Use in Minority Populations (STOMP) Genetics Consortium, US
- CYP2A6 genotype and smoking in China, Guangzhou, P.R. China
Scientific Focus
Current Research Interests
My research encompasses a collaborative, transdisciplinary initiative to translate molecular insights to genomically-tailored and patient-centered personalized medicine. Investigations are focused on the integration of three translational streams of investigation. The first stream triangulates genome-wide association studies with preclinical research using functional neuroimaging and other modalities aimed at elucidating biobehavioural mechanisms nicotine dependence and smoking cessation. The second stream investigates moderating effects of genotype on health-related behavior and drug response (particularly in smoking cessation treatment) in multiple ancestral populations. The third stream investigates the efficacy of genomically-tailored drug and behavioural therapies in prospective first-in-human clinical trials and evidenced-based medicine and policy research (e.g., systematic review/meta-analyses, cost-effectiveness analyses, healthcare delivery systems & educating the primary care workforce).
Publications
- Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers. J Hum Hypertens. 2013; (1): 24-30
- Biomarkers for Smoking Cessation. Clin Pharmacol Ther. 2013
- Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study. Nicotine Tob Res. 2013; (2): 518-26
- Association between CHRNA5 genetic variation at rs16969968 and brain reactivity to smoking images in nicotine dependent women. Drug Alcohol Depend. 2012; (1-3): 7-13
- Chronic psychosocial stressors and salivary biomarkers in emerging adults. Psychoneuroendocrinology. 2012; (8): 1158-70
- Dopamine D4 receptor gene variation moderates the efficacy of bupropion for smoking cessation. Pharmacogenomics J. 2012; (1): 86-92
Help